A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections in infants ...

Discover a study that highlights the importance of identifying high-risk children through biomarkers and better understanding ...

June 2, 2025 - Last Friday, the World Health Organization (WHO) published its first-ever position paper on immunization ...

The World Health Organization (WHO) has published its first ever position paper on immunization against respiratory syncytial ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis. This is the ...

The announcement comes as part of WHO’s broader effort to reduce child mortality, particularly in low- and middle-income ...

A single injection of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the ...

RSV infections in children needing primary care cause high economic impact due to outpatient costs and parental work absences ...